COMMUNIQUÉS West-GlobeNewswire

Labviva AI Procurement Solutions Help Research Universities Navigate Rising Costs and Funding Cuts
19/02/2026
AI-native platform delivers operational efficiencies and millions in annual cost savings to top research universities in the U.S. BOSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Labviva , the leading provider of life sciences [...]
ORYZON to Participate in Upcoming Events in February and March
19/02/2026
MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its [...]
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
19/02/2026
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for [...]
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
19/02/2026
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq [...]
Crescent Biopharma Announces Grants of Inducement Awards
19/02/2026
WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Reunion Neuroscience to Participate in Upcoming Investor Conferences
19/02/2026
MORRISTOWN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the [...]
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
19/02/2026
BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19 [...]
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
19/02/2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
19/02/2026
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug [...]
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
19/02/2026
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were [...]
Kane Biotech Expands Commercial Activities in the United States
19/02/2026
WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve ® [...]
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
19/02/2026
Blended finance award also includes up to €10 million in equity investment from the EIC Step Pharma’s lead product, dencatistat, expected to begin evaluation in phase 1b expansion cohorts for CTPS2 null ovarian and [...]
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
19/02/2026
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of [...]
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
19/02/2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. ( [...]
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19/02/2026
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the world As a [...]
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19/02/2026
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would [...]
Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships
19/02/2026
MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the [...]
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
19/02/2026
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Ipsen S.A. publie ses comptes consolidés 2025
19/02/2026
Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe Ipsen_Comptes Consolidés 2025_FR

Pages